SMART Antiviral Prize: Info Session & Live Q&A
Have questions about the SMART Antiviral Prize? Join this info sessions to learn more about the prize, Stage 1: Hit-to-Lead details, the submission process, and what we’re looking for.
What to Expect:
SMART Antiviral Prize Stage 1 overview and scope
Declaration of Intent and what happens next
Evaluation criteria and Review priority
Independent Validation of Results
You’ll also have the opportunity to engage directly with the VITAL team during a live Q&A.
Who should Attend:
Researchers, biotechs, innovators, AI and drug discovery teams, and others working on broad spectrum small molecule antiviral solutions.
Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions.
The BARDA Accelerator Network Hub, comprised of 5 hubs, will serve as a global network supporting early-stage companies from around the world developing next-generation medical countermeasures (MCMs). The Hubs are focused on Diagnostics/Medical Devices, Therapeutics/Vaccines, Digital Health Tools, Special Populations, and Enabling Technologies.
VITAL is a BARDA Accelerator Network Hub supporting the development and acceleration of next-generation therapeutic and vaccine platforms and technologies to promote health security. It is managed and operated by Start2 Group in partnership with Advise Connect Inspire (ACI) and BioInnovation Labs (BioLabs). VITAL provides a global innovation network to enable impactful collaborations between the U.S. and other health security communities and their innovation ecosystems around the world.